GFS Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

GFS Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$624K	–	179
2025 Q4	$624K	Hold	20,000	–	–	0.07%	119
2025 Q3	$404K	Buy	+20,000	New	+$351K	0.05%	133
2021 Q2	–	Sell	-36,200	Closed	-$418K	–	157
2021 Q1	$418K	Sell	36,200 -35,000	-49%	-$401K	0.1%	108
2020 Q4	$687K	Hold	71,200	–	–	0.18%	80
2020 Q3	$642K	Hold	71,200	–	–	0.2%	74
2020 Q2	$878K	Hold	71,200	–	–	0.27%	64
2020 Q1	$639K	Buy	71,200 +700	+1%	+$7.17K	0.2%	72
2019 Q4	$691K	Buy	70,500 +1,000	+1%	+$8.93K	0.18%	79
2019 Q3	$478K	Hold	69,500	–	–	0.13%	90
2019 Q2	$641K	Buy	69,500 +51,000	+276%	+$615K	0.18%	79
2019 Q1	$290K	Sell	18,500 -2,500	-12%	-$44.1K	0.09%	98
2018 Q4	$324K	Sell	21,000 -650	-3%	-$13.3K	0.09%	97
2018 Q3	$466K	Hold	21,650	–	–	0.12%	96
2018 Q2	$527K	Sell	21,650 -2,000	-8%	-$40.8K	0.11%	108
2018 Q1	$404K	Sell	23,650 -5,000	-17%	-$97.6K	0.08%	119
2017 Q4	$543K	Sell	28,650 -10,650	-27%	-$160K	0.12%	108
2017 Q3	$692K	Buy	39,300 +4,550	+13%	+$102K	0.16%	95
2017 Q2	$1.15M	Sell	34,750 -750	-2%	-$23.2K	0.25%	74
2017 Q1	$1.14M	Sell	35,500 -18,826	-35%	-$642K	0.23%	78
2016 Q4	$1.97M	Buy	54,326 +16,750	+45%	+$669K	0.41%	55
2016 Q3	$1.73M	Buy	37,576 +15,600	+71%	+$814K	0.38%	66
2016 Q2	$1.1M	Sell	21,976 -10,075	-31%	-$536K	0.27%	78
2016 Q1	$1.72M	Sell	32,051 -255	-0.8%	-$15K	0.45%	56
2015 Q4	$2.12M	Sell	32,306 -1,250	-4%	-$77.2K	0.63%	46
2015 Q3	$1.9M	Sell	33,556 -5,516	-14%	-$358K	0.66%	50
2015 Q2	$2.31M	Buy	39,072 +2,411	+7%	+$149K	0.76%	46
2015 Q1	$2.28M	Buy	36,661 +19,366	+112%	+$1.13M	0.8%	41
2014 Q4	$995K	Buy	17,295 +995	+6%	+$55.4K	0.4%	66
2014 Q3	$876K	Sell	16,300 -100	-0.6%	-$5.3K	0.36%	69
2014 Q2	$860K	Sell	16,400 -1,450	-8%	-$74.1K	0.35%	71
2014 Q1	$943K	Hold	17,850	–	–	0.37%	67
2013 Q4	$715K	Buy	17,850 +1,200	+7%	+$47.3K	0.35%	63
2013 Q3	$629K	Hold	16,650	–	–	0.33%	69
2013 Q2	$653K	Buy	+16,650	New	+$648K	0.38%	67

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GFS Advisors's TEVA Position: Q1 2026 in Review

GFS Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 20,000 shares — an estimated $624K sold.

GFS Advisors first reported a position in TEVA in Q2 2013 and held it in 34 quarters. The position peaked at $2.31M in Q2 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

GFS Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
GFS Advisors sold 20,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $624K.
GFS Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 34 quarters.
GFS Advisors's Teva Pharmaceuticals position peaked at $2.31M in Q2 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on GFS Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.